Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Volution flags better-than-expected full-year performance

(Sharecast News) - Volution Group said in an update on Thursday that it expects adjusted earnings per share for the financial year ending 31 July to come in slightly ahead of current market expectations, as the ventilation systems manufacturer reported stronger organic revenue growth and continued operational momentum in the second half. The FTSE 250 company now anticipated full-year organic revenue growth of over 5% in constant currency terms, improving from 4% at the half-year stage.

Total revenue growth was forecast to exceed 20%, bolstered by the eight-month contribution from Fantech, the group's largest acquisition to date, completed in December.

"Volution has delivered good progress during the second half of the year with organic growth expected to be slightly ahead of our target range of 3% to 5%," said chief executive Ronnie George.

"The acquisition of Fantech is going well, and integration has progressed in line with our expectations.

"I am hugely grateful to all our local teams' endeavours in supplying leading air quality solutions and providing our customers with 'healthy air, sustainably'."

In the UK, strong residential performance supported growth, particularly in new housebuilding, which benefited from low-carbon product demand and favourable regulations.

Refurbishment demand remained resilient despite broader market softness, while commercial revenue returned to growth after a weaker first half. Exports to Ireland were also strong.

In continental Europe, growth strengthened in the second half, with solid performances in central Europe and France, particularly through heat recovery offerings and expanded product ranges.

Volution said that in the Nordics, Swedish refurbishment remained firm, though new construction activity remained subdued.

Australasian market conditions remained mixed, with weaker demand in New Zealand offset by a stronger performance in Australia.

The group said Fantech's integration was proceeding well, adding that its revenue performance since acquisition was encouraging.

Group adjusted operating margins were expected to be broadly in line with the first half, with organic margin improvement offset by modest dilution from the Fantech acquisition.

The company reaffirmed its confidence in Fantech reaching Volution's 20% operating margin target over the medium term.

A currency translation impact from weaker Australian and New Zealand dollars reduced full-year revenue by £5m and adjusted operating profit by just over £1m.

Operating cash conversion was expected to exceed Volution's 90% target, supported by strong inventory and working capital management.

The company said its robust cash generation positioned it well for future investment and earnings-accretive acquisitions.

Volution said it would publish its full-year results on 9 October.

At 1014 BST, shares in Volution Group were up 3.32% at 653p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.